

	Candidate	Phase I			Phase I/II			Phase II			Phase III			Phase IV		
		Patients enrolled	Age range	Location	Patients enrolled	Age range (years)	Location	Patients enrolled	Age range	Location	Patients enrolled	Age range (years)	Location	Patients enrolled	Age range (years)	Location
Traditionally inactivated or weakened virus	CoronaVac				422	≥60	China				8870	≥60 & 18 - 59	Brazil			
					744	18 - 59					1620	18 - 59	Indonesia			
					552	3 - 17					13000	3 - 17	Turkey			
	Unnamed Inactive Vaccine - Wuhan				320	18 - 59	China				15000	≥18	UAE & China			
											600	≥18	Morocco&China			
	BBiP-CoV				540	18-80	China				15000	≥18	UAE & China			
											3000	18 - 65	Argentina			
	BBV152A, B, C				755	≥18 to ≤55	India				25800	≥18	India			
					124	12 - 65	India									
	QazCovid-in				244	≥18	Republic of Kazakhstan									
Unnamed Inactive Vaccine - Yunnan				942	18 - 59	China										
				471	≥60	China										
Unnamed inactivated SARS-CoV-2 Vaccine	180	≥18	China				1000	≥18	China							
Viral Vector	AD21222 (ChAdOx1 nCoV-19)				2000	18 - 65	South Africa				2000	18 - 55	United Kingdom			
					1112	18 - 55	United Kingdom	12390	≥18	United Kingdom	30000	≥18	United States			
					12	≥18	Japan				100	≥18	Russia			
	Ad5-nCoV	108	18 - 60	China				500	≥18	China	1600	≥18	India			
		89	18 - 60	China				481	≥6	China	40000	≥18	Pakistan			
								508	≥18	China	500	18 - 85	Russia			
	Gam-COVID-Vac (rAd26-S+rAd5-S)				38	18 - 60	Russia				40000	≥18	Russia			
					38	18 - 60	Russia	110	≥60	Russia	100	18 - 60	Belarus			
	Ad26.COV2.S	250	20 - 55	Japan	1045	18 - 55	United States & Belgium				60000	≥18	U.S., Brazil, Argentina, Chile, Colombia, Mexico, Peru, South Africa, Ukraine, Spain, France			
	DeIN1S-2019-nCoV-RBD-OPT1	60	≥18	China				720	18 - 60	China						
	TMV-083	90	18 - 55	Belgium & France												
	GRAd-COV2	90	18 - 55	Italy												
	Ad5-nCoV	144	≥18	China												
	Oral SARS-CoV-2 VX (VXA-CoV2-1)	48	18 - 54	United States												
	MVA-SARS-2-S	30	18 - 55	Germany												
IIBR-100				1040	18 - 85	Israel										
hAd5-S-Fusion+ N-ETSD	35	18 - 55	United States													
V590	252	≥18	United States													
Nucleic acids (RNA/DNA vaccines)	mRNA-1273	45	18 - 55	United States				600	≥18	United States	30000	≥18	United States			
		40	56 - 70 & ≥71	United States												
	BNT162(b1,b2,b3) (3 LNP-mRNAs)	195	18 - 55 & 65 - 85	United States	444	18 - 55 & 56 - 85	Germany				43998	≥16	U.S., Argentina, Brazil, South Africa, Turkey, Germany			
					144	18 - 55 & >55	China									
					120	18 - 55 & 56 - 85	Germany									
	CvriCoV (mRNA)	168	18 - 60	Belgium & Germany				691	18 - 60 & >60	Peru						
	LUNAR-COV19 (ARCT-021) (RNA)				92	21 - 55 & 56 - 80	Singapore									
	LNP-nCoVsaRNA	105	18 - 45	United Kingdom												
	Unnamed mRNA vaccine	168	18 - 80	China												
	INO-4800 (DNA)				160	19 - 64	South Korea									
					120	≥18	United States									
	AG0301-COV19 (DNA)				30	20 - 65	Japan									
				30	20 - 65	Japan										
ZyCoV-D (DNA)				1048	18 - 55	India										
GX-19 (DNA)				210	18 - 50	South Korea										
bacTRL-Spike (DNA)	12	≥18	Australia													
Protein subunit	NVX-CoV2373				1419	18 - 84	United States & Australia	2904	18 - 64	South Africa	9000	18 - 84	United Kingdom			
	KBP-COVID-19				180	18 - 49 & 50 - 70	United States									
	Unnamed Protein Subunit Vaccine				440	≥18	United States									
	Unnamed Recombinant Vaccine - Anhui	50	18 - 59	China	50	≥60	China	900	18 - 59	China						
	EpiVacCorona	100	18 - 60	Russia												
	SCB-2019	150	18 - 75	Australia												
	Unnamed Spike Protein Candidate	120	18 - 55	Australia												
		216	18 - 55 & ≥56	Australia												
	COVAX-19	40	18 - 65	Australia												
	MVC-COV1901	45	20 - 50	Taiwan												
	UB-612	60	20 - 55	Taiwan												
	Unnamed Recombinant Vaccine	168	≥18	China												
	FINLAY-FR-1 anti SARS-CoV-2				676	19 - 59 & 60 - 80	Cuba									
	CoVac-1	36	≥18	Germany												
	Unnamed adjuvanted protein subunit vaccine	360	18 - 55	India												
RBD-HBsAg VLPs				280	18 - 79	Australia										
Unnamed VLP Vaccine	180	18 - 55	Canada													
Repurposed	Measles-Mumps-Rubella Vaccine										200	18 - 50	Egypt	100	18 - 50	Netherlands
											60	18 - 70	United States			
	Bacille Calmette-Guerin										31545	≥18	Several	10964	≥18	Several
	Oral Polio Vaccine										3600	≥18	United States & New Zealand	3400	≥50	Guinea-Bissau
	IMM-101										1500	≥18	Canada			
	BACMUNE (MV130)										3312	18 - 65	Mexico			
	RUTI										315	≥18	Spain			
NasoVAX							96	≥18	United States							
Shingrix	250	≥65	United States													